A Phase 1 interventional study of CC-95266 and Fludarabine in Multiple Myeloma, sponsored by Juno Therapeutics, a Subsidiary of Celgene. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Juno Therapeutics, a Subsidiary of Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Multiple Myeloma by Bristol-Myers Squibb — 9 open to participants now, 18 under way, 6 of them phase 3. Multiple Myeloma · Bristol-Myers Squibb.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 43rd largest by enrollment of the 108 interventional ones that give a count, is one of 4 that started in 2021, is one of 40 in phase 1, and was the 124th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →9 of the 149 studies in Multiple Myeloma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Celgene · Sites in United States, Canada, China and 5 more countries
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Canada and 1 more country
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 38 · Phase 3 32
First in 2001; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 83 across the 108 interventional studies, 355 across the 35 observational. Of the 120 that completed or were terminated, 43 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Juno Therapeutics, a Subsidiary of Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Juno Therapeutics, a Subsidiary of Celgene is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
6 of the studies in Multiple Myeloma by Bristol-Myers Squibb that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT04975997Phase 3CelgeneOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-11-16 |
| NCT05688475Bristol-Myers SquibbA Rollover Study of CC-122 | 2026-11-30 |
| NCT03989414CelgeneA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | 2026-11-30 |
| NCT06988488CelgeneA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants in Part A, and Part B Cohort A, and Part B Cohort B must have received at least 3 prior anti-myeloma treatment regimens (note: induction with or without hematopoietic stem cell transplant () and with or without maintenance therapy is considered one regimen).Subjects in Part B Cohort C only must have received at least 1 but not greater than 3 prior anti-myeloma treatment regimens, including a proteasome inhibitor and immunomodulatory agent including:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CC-95266 · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Bendamustine
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Number of participants with Adverse Events (AEs)
Time frame: Up to 2 years after CC-95266 infusion
Number of participants with significant laboratory abnormalities
Time frame: Up to 2 years after CC-95266 infusion
Number of participants with Dose Limiting Toxicities (DLTs)
Time frame: Up to 2 years after CC-95266 infusion
Maximum Tolerated Dose (MTD)
Time frame: Up to 2 years after CC-95266 infusion
Recommended Phase 2 Dose (RP2D)
Time frame: Up to 2 years after CC-95266 infusion
Pharmacokinetics - Maximum plasma concentration of drug (Cmax)
Time frame: Up to 2 years after CC-95266 infusion
Pharmacokinetics - Time to peak (maximum) serum concentration (tmax)
Time frame: Up to 2 years after CC-95266 infusion
Pharmacokinetics - Area under the curve for days 1-29 after CC-95266 infusion (AUC1-29)
Time frame: Up to 2 years after CC-95266 infusion
Overall response rate (ORR)
Time frame: Up to 2 years after CC-95266 infusion
Complete response rate (CRR)
Time frame: Up to 2 years after CC-95266 infusion
Very good partial response (VGPR) or better
Time frame: Up to 2 years after CC-95266 infusion
Duration of response (DOR)
Time frame: Up to 2 years after CC-95266 infusion
Duration of complete response (DOCR)
Time frame: Up to 2 years after CC-95266 infusion
Time to response (TTR)
Time frame: Up to 2 years after CC-95266 infusion
Time to complete response (TTCR)
Time frame: Up to 2 years after CC-95266 infusion
Progression-free survival (PFS)
Time frame: Up to 2 years after CC-95266 infusion
Overall survival (OS)
Time frame: Up to 2 years after CC-95266 infusion
Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.celgene.com
Ran from Feb 2021 to primary completion in Dec 2025, 57 months.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 57 months is above that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arlocabtagene autoleucel
Juno Therapeutics, a Subsidiary of Celgene →